IGF1 and Cirrhosis: Although IGF-1 and IGBP-3 have been reported to be altered in previous studies performed in atherosclerosis and other cardiovascular diseases, we found no significant differences between the two peptides among patients with hepatitis, cirrhosis or pancreatitis [55–56].